BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12918521)

  • 21. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 22. [New therapeutic targets and strategies in lung cancer].
    Sánchez De Cos Escuín J
    Arch Bronconeumol; 2002 Aug; 38(8):386-91. PubMed ID: 12199921
    [No Abstract]   [Full Text] [Related]  

  • 23. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
    Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
    Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.
    O'Dwyer ME; Druker BJ
    Curr Cancer Drug Targets; 2001 May; 1(1):49-57. PubMed ID: 12188891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
    Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
    Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
    [No Abstract]   [Full Text] [Related]  

  • 26. Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.
    Druker BJ
    J Hematother Stem Cell Res; 2001 Dec; 10(6):721-4. PubMed ID: 11798498
    [No Abstract]   [Full Text] [Related]  

  • 27. [Molecular target therapy for malignant tumors].
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
    [No Abstract]   [Full Text] [Related]  

  • 28. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I; Blay JY
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract]   [Full Text] [Related]  

  • 29. Hits and misses in targeting pediatric cancers.
    Bernstein ML
    Pediatr Blood Cancer; 2009 Jul; 52(7):751-2. PubMed ID: 19185009
    [No Abstract]   [Full Text] [Related]  

  • 30. New drugs in acute myeloid leukemia.
    Grever MR
    Clin Adv Hematol Oncol; 2003 Aug; 1(8):456-9. PubMed ID: 16258431
    [No Abstract]   [Full Text] [Related]  

  • 31. KIT and PDGF as targets.
    Verweij J
    Cancer Treat Res; 2004; 120():117-27. PubMed ID: 15217221
    [No Abstract]   [Full Text] [Related]  

  • 32. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
    Nishida T; Yoshidome K; Tori M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():452-6. PubMed ID: 23513883
    [No Abstract]   [Full Text] [Related]  

  • 33. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

  • 34. Myelofibrosis: biology and treatment options.
    Cervantes F
    Eur J Haematol Suppl; 2007 Oct; (68):13-7. PubMed ID: 17727559
    [No Abstract]   [Full Text] [Related]  

  • 35. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate.
    George DJ
    Urology; 2002 Sep; 60(3 Suppl 1):115-21; discussion 122. PubMed ID: 12231066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
    Gambacorti C
    Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
    Heinrich MC; Corless CL
    Cancer Treat Res; 2004; 120():129-50. PubMed ID: 15217222
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
    Becker JC; Muller-Tidow C; Serve H; Domschke W; Pohle T
    World J Gastroenterol; 2006 Jun; 12(21):3297-305. PubMed ID: 16733844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
    Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
    Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.